Breaking News Instant updates and real-time market news.

F

Ford

$9.56

0.04 (0.42%)

08:51
08/20/18
08/20
08:51
08/20/18
08:51

Ford risks high, but so is potential reward, says Morgan Stanley

Morgan Stanley analyst Adam Jonas believes Ford announcing plans to spend $11B on restructuring and then canceling its investor day may have may have the unintended consequence of raising expectations for a "big bang" of action. While acknowledging the wide range of potential outcomes, Jonas has an estimate for how Ford could recognize its planned $11B in restructuring charges over a 3-5 year period to achieve annual cost reductions of about $4B, giving it a payback period of just under 3 years that would "usually [be] a very good use of capital" by automotive standards, he tells investors. Jonas maintains an Overweight rating on Ford with a $15 price target, contending that the "risks are high, but so is the potential reward."

  • 31

    Aug

F Ford
$9.56

0.04 (0.42%)

07/20/18
JPMS
07/20/18
NO CHANGE
JPMS
Overweight
JPMorgan says buy GM, sell Tesla into Q2 earnings reports
JPMorgan analyst Ryan Brinkman forecasts lower than consensus Q2 earnings for Ford (F) and higher than Street earnings for General Motors (GM). Both companies are likely to be impacted by higher commodity costs during the quarter, although the decline in spot prices subsequent to the quarter should limit impact to the full year, Brinkman tells investors in a research note previewing the Q2 earnings for the automakers. The analyst is also concerned about the potential for a "large loss and accompanying large cash outflow" at Tesla in Q2 to "make the bridge" to GAAP profitability and positive cash generation in the second half of the year. Brinkman maintains Overweight ratings on GM and Ford, with a preference for GM shares. He also keeps his cautious Underweight rating on Tesla shares, seeing 44% downside to his $180 December 2018 price target.
07/20/18
07/20/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. BOFA CUTS YUM CHINA TO UNDERPERFORM: BofA Merrill Lynch analyst Chen Luo downgraded Yum China (YUMC) to Underperform from Neutral and cut its price target to $34 from $44.30. Luo said he expects Yum China to continue to underperform given a likely peak in KFC trends amid China's weakening macro environment, a likely prolonged turnaround at Pizza Hut combined with heavy costs, a slowdown in Chinese consumer consumption, and RMB depreciation. Yum China is down 4.8% in late morning trading. CREDIT SUISSE CUTS FIVE BELOW TO NEUTRAL: Credit Suisse analyst Judah Frommer downgraded Five Below (FIVE) to Neutral from Outperform, telling investors that he is moving to the sidelines as he sees risk/reward balanced at current levels given the stock's material outperformance and back-half comp acceleration that he believes is priced into shares. Frommer keeps his $110 price target and says Five Below remains one of the most differentiated concepts in retail. Five Below is down 4.4% in late morning trading. BAIRD MORE CAUTIOUS ON DRUG SUPPLY CHAIN: Baird analyst Eric Coldwell downgraded Express Scripts (ESRX), AmerisourceBergen (ABC), and McKesson (MCK), all to Neutral from Outperform, citing the heavy political attack in recent weeks against pharmacy benefit managers and members of the drug supply chain. Among them, he said AmerisourceBergen remains his preferred name, but he cannot justify putting new money to work in these names in the current environment. SUNTRUST STARTS VIKING WITH A BUY: SunTrust analyst Edward Nash initiated Viking Therapeutics (VKTX) with a Buy rating and a price target of $14, saying its VK2809 drug for lipid disorders "has the potential to become a promising treatment by addressing multiple metabolic issues" associated with the non-alcoholic steatohepatitis disease, or NASH. Viking is up 8.3% in late morning trading. JPMORGAN SAYS BUY GM, SELL TESLA INTO EARNINGS: JPMorgan analyst Ryan Brinkman forecast lower than consensus Q2 earnings for Ford (F) and higher than consensus earnings for General Motors (GM). The analyst is also concerned about the potential for a "large loss and accompanying large cash outflow" at Tesla (TSLA) in Q2 to "make the bridge" to GAAP profitability and positive cash generation in the second half of the year. Brinkman maintained Overweight ratings on GM and Ford, with a preference for GM shares. He also kept his cautious Underweight rating on Tesla shares, seeing 44% downside to his $180 December 2018 price target.
07/24/18
PIPR
07/24/18
NO CHANGE
Target $57
PIPR
Overweight
General Motors outperforming Ford in China, says Piper Jaffray
While both would suffer in a trade war, it is clear that General Motors (GM) is outperforming Ford (F) in China, Piper Jaffray analyst Alexander Potter tells investors in a research note. The analyst views GM's China business as stable, with a growing presence in luxury. He thinks Cadillac represented 16.7% of GM's Q2 revenue in China, versus 13.6% in 2017, which should boost margins. Until its "new product blitz gains momentum, Ford's China business will likely continue bleeding," Potter contends. He notes the company's Ford's retail sales in China declined by 38% year-over-year in June. The analyst keeps an Overweight rating on GM and a Neutral rating on Ford.
08/14/18
NOMU
08/14/18
NO CHANGE
Target $9
NOMU
Neutral
Ford price target lowered to $9 from $10 at Nomura Instinet
Nomura Instinet analyst Anindya Das lowered his price target for Ford to $9 after reducing fiscal 2018 earnings per share estimate by 17% to $1.20. The analyst lowered his outlook for Ford's Asia Pacific operations based on first half of 2018 sales trends and also sees Europe becoming more difficult. Das keeps a Neutral rating on Ford shares.

TODAY'S FREE FLY STORIES

ABBV

AbbVie

$88.70

-0.81 (-0.90%)

05:33
01/23/19
01/23
05:33
01/23/19
05:33
Initiation
AbbVie initiated  »

AbbVie assumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 28

    Jan

  • 18

    May

PFE

Pfizer

$42.26

-0.26 (-0.61%)

05:31
01/23/19
01/23
05:31
01/23/19
05:31
Downgrade
Pfizer rating change  »

Pfizer downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 29

    Jan

  • 18

    May

XOM

Exxon Mobil

$71.89

-1.09 (-1.49%)

05:30
01/23/19
01/23
05:30
01/23/19
05:30
Hot Stocks
Exxon Mobil, REG enter joint research agreement with Clariant »

ExxonMobil and Renewable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 10

    Feb

MYL

Mylan

$28.90

-0.68 (-2.30%)

05:30
01/23/19
01/23
05:30
01/23/19
05:30
Downgrade
Mylan rating change  »

Mylan downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZTS

Zoetis

$84.07

-0.55 (-0.65%)

05:29
01/23/19
01/23
05:29
01/23/19
05:29
Initiation
Zoetis initiated  »

Zoetis initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

MDGL

Madrigal Pharmaceuticals

$114.07

-5.76 (-4.81%)

05:28
01/23/19
01/23
05:28
01/23/19
05:28
Initiation
Madrigal Pharmaceuticals initiated  »

Madrigal Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$80.66

-2.42 (-2.91%)

05:27
01/23/19
01/23
05:27
01/23/19
05:27
Initiation
Alnylam initiated  »

Alnylam initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ELAN

Elanco

$31.00

-0.53 (-1.68%)

05:26
01/23/19
01/23
05:26
01/23/19
05:26
Initiation
Elanco initiated  »

Elanco initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$18.75

-0.06 (-0.32%)

05:24
01/23/19
01/23
05:24
01/23/19
05:24
Upgrade
Teva rating change  »

Teva upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

LBRT

Liberty Oilfield Services

$14.90

-0.33 (-2.17%)

05:23
01/23/19
01/23
05:23
01/23/19
05:23
Hot Stocks
Liberty Oilfield Services announces additional $100M share repurchase plan »

Liberty Oilfield Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Feb

ICPT

Intercept

$110.76

-2.56 (-2.26%)

05:22
01/23/19
01/23
05:22
01/23/19
05:22
Initiation
Intercept initiated  »

Intercept initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

LLY

Eli Lilly

$117.06

0.51 (0.44%)

05:19
01/23/19
01/23
05:19
01/23/19
05:19
Initiation
Eli Lilly initiated  »

Eli Lilly initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 13

    Feb

  • 18

    May

NKTR

Nektar

$44.74

-1.48 (-3.20%)

, BMY

Bristol-Myers

$49.71

-0.44 (-0.88%)

05:17
01/23/19
01/23
05:17
01/23/19
05:17
Recommendations
Nektar, Bristol-Myers, Pfizer analyst commentary  »

Mizuho sees…

NKTR

Nektar

$44.74

-1.48 (-3.20%)

BMY

Bristol-Myers

$49.71

-0.44 (-0.88%)

PFE

Pfizer

$42.26

-0.26 (-0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 28

    Jan

  • 29

    Jan

  • 28

    Feb

  • 18

    May

  • 20

    May

APHA

Aphria

$7.07

0.41 (6.16%)

05:12
01/23/19
01/23
05:12
01/23/19
05:12
Hot Stocks
Aphria urges holder to take no action regarding takeover bid by Green Growth »

Aphria confirmed that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COHU

Cohu

$17.43

-0.295 (-1.66%)

05:11
01/23/19
01/23
05:11
01/23/19
05:11
Downgrade
Cohu rating change  »

Cohu downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANSS

Ansys

$160.84

-0.79 (-0.49%)

05:09
01/23/19
01/23
05:09
01/23/19
05:09
Hot Stocks
Ansys to acquire Granta Design, terms not disclosed »

ANSYS announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$91.50

-3.02 (-3.20%)

05:09
01/23/19
01/23
05:09
01/23/19
05:09
Downgrade
Lowe's rating change  »

Lowe's downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 27

    Feb

  • 03

    Mar

ATRA

Atara Biotherapeutics

$35.47

-1.72 (-4.62%)

05:05
01/23/19
01/23
05:05
01/23/19
05:05
Initiation
Atara Biotherapeutics initiated  »

Mizuho starts Atara…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGCO

Agco

$62.76

-1.93 (-2.98%)

04:59
01/23/19
01/23
04:59
01/23/19
04:59
Downgrade
Agco rating change  »

Agco downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 06

    Feb

  • 07

    Feb

LOGI

Logitech

$33.69

0.24 (0.72%)

04:57
01/23/19
01/23
04:57
01/23/19
04:57
Upgrade
Logitech rating change  »

Logitech upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNP

TEN, Ltd.

$3.30

-0.09 (-2.65%)

04:56
01/23/19
01/23
04:56
01/23/19
04:56
Downgrade
TEN, Ltd. rating change  »

TEN, Ltd. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

04:55
01/23/19
01/23
04:55
01/23/19
04:55
Conference/Events
Stephens building materials analyst to hold group dinner »

Building Materials…

HSKA

Heska

$97.20

0.46 (0.48%)

04:55
01/23/19
01/23
04:55
01/23/19
04:55
Conference/Events
Heska management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

04:55
01/23/19
01/23
04:55
01/23/19
04:55
Conference/Events
UBS software analyst to hold an analyst/industry conference call »

Software Analyst Jennifer…

ENLK

EnLink Midstream Partners

$13.30

-0.28 (-2.06%)

, ENLC

EnLink Midstream

$11.51

-0.24 (-2.04%)

04:55
01/23/19
01/23
04:55
01/23/19
04:55
Conference/Events
EnLink Midstream Companies to hold a special shareholder meeting »

Special Shareholder…

ENLK

EnLink Midstream Partners

$13.30

-0.28 (-2.06%)

ENLC

EnLink Midstream

$11.51

-0.24 (-2.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.